New drug targets Hard-to-Treat cancers in asian patients
NCT ID NCT07077434
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called navlimetostat in 32 Japanese and Chinese patients with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goal is to check the drug's safety and how the body processes it. Participants must have tumors that cannot be removed by surgery or have spread, and have already tried other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510000, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150081, China
-
Kanagawa cancer center
RECRUITINGYokohama, Kanagawa, 2418515, Japan
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
-
Shizuoka Cancer Center
RECRUITINGSunto-gun, Shizuoka, 411-8777, Japan
-
The Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
-
The First Affiliated Hospital of Xinxiang Medical University
RECRUITINGXinxiang, Henan, 453100, China
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.